Biogen (BIIB) Holder Terril Brothers Trimmed Its Stake by $309,036; As Aetna (AET) Share Price Rose, Davis Selected Advisers Has Lifted Stake

August 10, 2018 - By Ricky Cave

Biogen Inc. (NASDAQ:BIIB) Logo

Terril Brothers Inc decreased its stake in Biogen Inc (BIIB) by 1.97% based on its latest 2018Q1 regulatory filing with the SEC. Terril Brothers Inc sold 1,132 shares as the company’s stock declined 1.31% with the market. The institutional investor held 56,436 shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $15.45 million, down from 57,568 at the end of the previous reported quarter. Terril Brothers Inc who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $68.68B market cap company. The stock decreased 1.72% or $5.97 during the last trading session, reaching $340.93. About 659,202 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 13.14% since August 10, 2017 and is uptrending. It has outperformed by 0.57% the S&P500. Some Historical BIIB News: 12/03/2018 – BIOGEN TO BUY FROM PFIZER FIRST-IN-CLASS PHASE 2B READY ASSET; 05/04/2018 – BIOGEN INC – BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018; 12/03/2018 – Biogen Announces New Interim Phase 2 Results From NURTURE; 20/04/2018 – So $BIIB called recent M&A multiples “frothy”… $AVXS $JUNO $KITE; 05/04/2018 – BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCT. 16, 2018; 01/05/2018 – Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab; 17/04/2018 – Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and; 14/05/2018 – Primecap Adds Moody’s, Exits Constellium, Cuts Biogen: 13F; 24/04/2018 – BIOGEN INC – QTRLY TYSABRI REVENUE OF $$462 MLN VS. $545 MLN REPORTED LAST YEAR; 30/04/2018 – M&G – Episode Growth Exits Biogen

Davis Selected Advisers increased its stake in Aetna Inc. (AET) by 40.38% based on its latest 2018Q1 regulatory filing with the SEC. Davis Selected Advisers bought 1.31M shares as the company’s stock rose 1.59% while stock markets declined. The institutional investor held 4.57 million shares of the medical specialities company at the end of 2018Q1, valued at $772.32 million, up from 3.26 million at the end of the previous reported quarter. Davis Selected Advisers who had been investing in Aetna Inc. for a number of months, seems to be bullish on the $63.48 billion market cap company. The stock increased 0.15% or $0.3 during the last trading session, reaching $194.08. About 610,911 shares traded. Aetna Inc. (NYSE:AET) has risen 22.94% since August 10, 2017 and is uptrending. It has outperformed by 10.37% the S&P500. Some Historical AET News: 02/05/2018 – CVS Is `Moving Forward’ With Aetna Deal, Suspends Buyback Plan; 01/05/2018 – Aetna 1Q Effective Tax Rate 16.8%; 17/04/2018 – AETNA REALIGNED SEGMENTS W/ MANAGEMENT STRUCTURE FOR 1Q; 17/04/2018 – Aetna Changes Come Amid Pending Transaction With CVS Health; 03/04/2018 – TriCare Earns Top Customer Experience Ratings for Health Plans, According to Temkin Group; 28/03/2018 – FDA’S GOTTLIEB LOOKING AT POLICIES TO STIMULATE BIOSIMILARS UPTAKE; 27/03/2018 – Aetna Will Pass Drug Rebates Along To Portion Of Members — MarketWatch; 01/05/2018 – Aetna 1Q Adjusted Pretax Margin 10.1%; 18/04/2018 – AETNA INTERNATIONAL ENTERS PARTNERSHIP DEAL W/ HUMANIS; 13/03/2018 – Aetna Shareholders Overwhelmingly Approve Proposed Acquisition by CVS Health

Among 33 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 25 have Buy rating, 0 Sell and 8 Hold. Therefore 76% are positive. Biogen Idec Inc. had 142 analyst reports since July 23, 2015 according to SRatingsIntel. As per Wednesday, June 14, the company rating was maintained by Morgan Stanley. Robert W. Baird maintained the shares of BIIB in report on Friday, August 25 with “Hold” rating. The company was maintained on Tuesday, April 24 by Guggenheim. The firm has “Buy” rating by Bank of America given on Wednesday, October 18. The company was maintained on Tuesday, October 24 by Goldman Sachs. The rating was maintained by SunTrust on Tuesday, April 24 with “Buy”. The rating was downgraded by Robert W. Baird on Monday, July 27 to “Neutral”. Raymond James maintained Biogen Inc. (NASDAQ:BIIB) rating on Thursday, December 29. Raymond James has “Strong Buy” rating and $386 target. Bernstein maintained the stock with “Buy” rating in Tuesday, November 28 report. Morgan Stanley maintained it with “Overweight” rating and $366 target in Friday, July 13 report.

Since February 15, 2018, it had 1 buy, and 4 insider sales for $12.01 million activity. $12.96 million worth of Biogen Inc. (NASDAQ:BIIB) was bought by DENNER ALEXANDER J on Wednesday, April 25.

Investors sentiment decreased to 1.07 in Q1 2018. Its down 0.10, from 1.17 in 2017Q4. It fall, as 69 investors sold BIIB shares while 305 reduced holdings. 92 funds opened positions while 308 raised stakes. 178.22 million shares or 1.35% less from 180.65 million shares in 2017Q4 were reported. Hsbc Public Ltd Co holds 0.15% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 364,100 shares. Stonebridge Capital Management, a California-based fund reported 2,661 shares. Kentucky Retirement Insurance Tru Fund, Kentucky-based fund reported 4,843 shares. Bartlett & Com Ltd Limited Liability Company reported 40 shares. Alphaone Inv Services Limited Liability Corp reported 0.05% in Biogen Inc. (NASDAQ:BIIB). Advisor Prtn Limited Liability Com owns 4,539 shares. Trust Co Of Vermont holds 0.08% in Biogen Inc. (NASDAQ:BIIB) or 3,132 shares. Tirschwell And Loewy Inc holds 72,227 shares. Cubist Systematic Strategies holds 0.06% or 3,798 shares. Geode Capital Llc invested in 2.59M shares. Factory Mutual stated it has 178,200 shares. 6,442 are owned by Amica Pension Fund Board Of Trustees. Martingale Asset Mgmt LP invested in 11,560 shares or 0.04% of the stock. Orbimed Advsr Lc holds 1.04 million shares. Gam Holdings Ag holds 0.36% or 37,771 shares.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on October, 23. They expect $6.58 earnings per share, up 4.28% or $0.27 from last year’s $6.31 per share. BIIB’s profit will be $1.33 billion for 12.95 P/E if the $6.58 EPS becomes a reality. After $5.80 actual earnings per share reported by Biogen Inc. for the previous quarter, Wall Street now forecasts 13.45% EPS growth.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Seekingalpha.com which released: “Biogen Hits A Potential Home Run” on August 07, 2018, also Seekingalpha.com with their article: “Biogen Went Up Despite Unclear Data, Caution Warranted” published on July 17, 2018, Seekingalpha.com published: “Buy Biogen For Alzheimer’s Therapy Pipeline” on August 07, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: 247Wallst.com and their article: “Why Have Short Sellers Backed Off Major Biotechs?” published on August 10, 2018 as well as Seekingalpha.com‘s news article titled: “Biogen And Eisai: Let The Alzheimer’s Arguing Commence” with publication date: July 27, 2018.

Investors sentiment decreased to 0.68 in 2018 Q1. Its down 0.15, from 0.83 in 2017Q4. It is negative, as 83 investors sold AET shares while 335 reduced holdings. 78 funds opened positions while 208 raised stakes. 269.52 million shares or 2.24% less from 275.71 million shares in 2017Q4 were reported. Moreover, Sei has 0.14% invested in Aetna Inc. (NYSE:AET). Moreover, Assetmark has 0.01% invested in Aetna Inc. (NYSE:AET). Earnest Prns Limited Com accumulated 156 shares. First Personal Financial has invested 0.01% in Aetna Inc. (NYSE:AET). Oakwood Capital Ltd Limited Liability Company Ca holds 2.09% of its portfolio in Aetna Inc. (NYSE:AET) for 29,033 shares. Putnam Fl Inv Management invested in 1.14% or 74,071 shares. Roanoke Asset Mgmt New York, New York-based fund reported 2,000 shares. Halsey Associate Ct owns 2,550 shares for 0.08% of their portfolio. First Republic Investment Mgmt stated it has 22,216 shares or 0.03% of all its holdings. Ballentine Ptnrs, Massachusetts-based fund reported 2,544 shares. Vantage Inv Advsr has invested 1.75% in Aetna Inc. (NYSE:AET). Michael Susan Dell Foundation reported 22.83% of its portfolio in Aetna Inc. (NYSE:AET). Commerce Bancorporation stated it has 0.04% of its portfolio in Aetna Inc. (NYSE:AET). Sun Life has invested 0% in Aetna Inc. (NYSE:AET). Canandaigua Savings Bank Com has 9,966 shares.

Among 24 analysts covering Aetna (NYSE:AET), 12 have Buy rating, 0 Sell and 12 Hold. Therefore 50% are positive. Aetna had 76 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank with “Hold” on Monday, August 7. On Tuesday, September 12 the stock rating was maintained by Argus Research with “Buy”. The stock of Aetna Inc. (NYSE:AET) has “Mkt Perform” rating given on Monday, November 14 by Bernstein. RBC Capital Markets maintained the stock with “Buy” rating in Monday, December 4 report. As per Monday, June 11, the company rating was maintained by Cantor Fitzgerald. The stock of Aetna Inc. (NYSE:AET) has “Hold” rating given on Tuesday, February 2 by Jefferies. Jefferies maintained Aetna Inc. (NYSE:AET) on Tuesday, January 30 with “Hold” rating. As per Monday, December 18, the company rating was maintained by Wells Fargo. The stock of Aetna Inc. (NYSE:AET) earned “Neutral” rating by Piper Jaffray on Wednesday, January 4. Morgan Stanley initiated the stock with “Overweight” rating in Wednesday, June 7 report.

Davis Selected Advisers, which manages about $48.17B and $23.12 billion US Long portfolio, decreased its stake in Essex Property Trust Inc. (NYSE:ESS) by 23,110 shares to 60,326 shares, valued at $14.52M in 2018Q1, according to the filing. It also reduced its holding in Liberty Interactive Corp. Qvc Group Series A (NASDAQ:QVCA) by 79,186 shares in the quarter, leaving it with 1.97 million shares, and cut its stake in Noah Holdings Ltd. Ads (NYSE:NOAH).

Aetna Inc. (NYSE:AET) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts